Cassava then released the altered data in a press release and investor deck, which led the SEC to allege that the company and ...

GLP-1 agonist Wegovy (semaglutide) brought in DKK 17.3 billion ($2.49 billion) in the period, restoring earlier levels of ...

CD40 agonists have had mixed results in cancer to date, with Roche discontinuing its selicrelumab candidate after ...

It is all over bar the shouting win for the US election, with Donald Trump set to claim the Presidency, potentially with the ...

Read Deep Dive: Patients & Partnerships in full pharmaphorum’s digital magazine Deep Dive provides objective, issue-driven ...

AstraZeneca's shares have fallen more than 8% on speculation about an anti-corruption probe in China, its second-largest ...

BEAM-101 is an ex vivo genetic therapy delivered as part of an autologous haematopoietic stem cell transplant (HSCT) after a conditioning chemotherapy regimen to destroy the bone marrow and allow it ...

Field medical education before launch is linked to greater launch success, improving treatment adoption by up to 50%. New ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated ...

Incyte filed a lawsuit to try to block the launch of Leqselvi, claiming that the drug infringed a US patent (No. 9,662,335) ...

Lawyers for AstraZeneca, Bristol-Myers Squibb, and Johnson & Johnson argued at a panel hearing in Philadelphia late last week ...

With a mix of breakout sessions, hands-on workshops, and in-depth discussions, learning from real-world case studies that ...